Abstract

AbstractHere, we developed a vaccine delivery system that attains sustained release of antigens (ovalbumin; model antigen) and adjuvants (CpG‐DNA; oligodeoxynucleotides containing unmethylated cytosine‐guanine motifs) using biodegradable temperature‐responsive injectable polymers (IP). We previously prepared a biodegradable IP system that exhibited a temperature‐responsive sol‐to‐gel transition and subsequent chemical cross‐linking. The IP system used triblock copolymers, poly(ε‐caprolactone‐co‐glycolide)‐b‐poly(ethylene glycol)‐b‐poly(ε‐caprolactone‐co‐glycolide) (tri‐PCG) and a polymer whose termini were converted to N‐hydroxysuccinimide esters (tri‐PCG‐OSu). OVA and CpG‐DNA sustained release was achieved using tri‐PCG‐based IP systems in vitro. Moreover, the release of CpG‐DNA was delayed using an IP system containing tri‐PCG‐OSu mixed with poly(l‐lysine) (PLL). Subcutaneous administration of the tri‐PCG‐based IP gel vaccine induced stronger humoral and cellular immune responses in mice than in those without IP administration. The Tri‐PCG‐OSu IP gel maintained high OVA‐specific IgG titers for 22 weeks. In contrast, the tri‐PCG IP gel exhibited a relatively rapid release of CpG DNA in vitro, predominantly inducing cellular immune responses. Furthermore, the tri‐PCG IP gel showed a potent anti‐tumor effect against OVA‐expressing T lymphoma (E.G7‐OVA) and extended the survival duration of mice. Therefore, tri‐PCG‐based IP systems are promising vaccine platforms for controlling the release of antigens and adjuvants to enhance the humoral and cellular immune responses.This article is protected by copyright. All rights reserved

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call